{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:56:10Z","timestamp":1793141770715,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20286"],"award-info":[{"award-number":["U22A20286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20286"],"award-info":[{"award-number":["U22A20286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20286"],"award-info":[{"award-number":["U22A20286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20286"],"award-info":[{"award-number":["U22A20286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mianyang Health Committee project","award":["202040"],"award-info":[{"award-number":["202040"]}]},{"name":"Mianyang Health Committee project","award":["202040"],"award-info":[{"award-number":["202040"]}]},{"name":"Mianyang Health Committee project","award":["202040"],"award-info":[{"award-number":["202040"]}]},{"name":"Key Research and Development Program of Science and Technology Department of Sichuan Province","award":["2022YFS0612"],"award-info":[{"award-number":["2022YFS0612"]}]},{"name":"Key Research and Development Program of Science and Technology Department of Sichuan Province","award":["2022YFS0612"],"award-info":[{"award-number":["2022YFS0612"]}]},{"name":"Key Research and Development Program of Science and Technology Department of Sichuan Province","award":["2022YFS0612"],"award-info":[{"award-number":["2022YFS0612"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Numerous clinical studies have explored sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus (T2DM), and SGLT2i were proved to significantly reduce CHF hospitalization, cardiovascular death, cardiovascular mortality, all-cause mortality and myocardial infarction in patients with or without T2DM. However, only a limited few have investigated the effects of SGLT-2i on HF disease-specific health status and cardiac function. This meta-analysis aims to assess the effects of SGLT2i on disease-specific health status and cardiac function in CHF patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive search was conducted of trials by searching in PubMed, EMBASE, CENTRAL, Scopus, and Web of Science, and two Chinese databases (CNKI and Wanfang), Clinical Trials (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>) were also searched.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 18 randomized controlled trials (RCTs) involving 23,953 participants were included in the meta-analysis. The effects of SGLT2 inhibitors were compared with control or placebo groups in CHF with or without T2DM. The SGLT2 inhibitors group exhibited a significant reduction in pro b-type natriuretic peptide (NT-proBNP) levels by 136.03 pg\/ml (95% confidence interval [CI]: \u2212253.36, \u2212\u200918.70; P\u2009=\u20090.02). Additionally, a greater proportion of patients in the SGLT2 inhibitors group showed a\u2009\u2265\u200920% decrease in NT-proBNP (RR\u2009=\u20091.45, 95% CI [0.92, 2.29], p\u2009=\u20090.072). However, no statistically significant difference was observed for the effects on B-type natriuretic peptide (BNP). The use of SGLT-2 inhibitors led to a noteworthy improvement in LVEF by 2.79% (95% CI [0.18, 5.39];P\u2009=\u20090.036). In terms of health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance, SGLT2 inhibitors led to a significant improvement in KCCQ clinical summary (KCCQ-CS) score (WMD\u2009=\u20091.7, 95% CI [1.67, 1.73], P\u2009&lt;\u20090.00001), KCCQ overall summary (KCCQ-OS) score (WMD\u2009=\u20091.73, 95% CI [0.94, 2.52], P\u2009&lt;\u20090.00001), and KCCQ total symptom (KCCQ-TS) score (WMD\u2009=\u20092.88, 95% CI [1.7, 4.06], P\u2009&lt;\u20090.00001). Furthermore, the occurrence of KCCQ-CS and KCCQ-OS score increases\u2009\u2265\u20095 points had relative risks (RR) of 1.25 (95% CI [1.11, 1.42], P\u2009&lt;\u20090.00001) and 1.15 (95% CI [1.09, 1.22], P\u2009&lt;\u20090.00001), respectively. Overall, SGLT2 inhibitors increased the 6-minute walk distance by 23.98\u00a0m (95% CI [8.34, 39.62]; P\u2009=\u20090.003) compared to control\/placebo from baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The SGLT2 inhibitors treatment offers an effective strategy for improving NT-proBNP levels, Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance in CHF with or without T2DM. These findings indicate that SGLT2i improve cardiac function and health status in CHF with or without T2DM, and provide valuable guidance for clinicians making treatment decisions for patients with CHF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-02042-9","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:02:53Z","timestamp":1704290573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongzhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pijun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XunMei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"36","key":"2042_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic Heart Failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"10","key":"2042_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 update: a Report from the American Heart Association. Circulation. 2019;139(10):e56\u201328.","journal-title":"Circulation"},{"issue":"6","key":"2042_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jcpt.13243","volume":"45","author":"Y Feng","year":"2020","unstructured":"Feng Y, Yin Y, Deng R, et al. Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2020;45(6):1235\u201343.","journal-title":"J Clin Pharm Ther"},{"issue":"24","key":"2042_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"22","key":"2042_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2042_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"2042_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with Heart Failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2042_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"2042_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with Diabetes and recent worsening Heart Failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2042_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/clc.23581","volume":"44","author":"S Bryan Richard","year":"2021","unstructured":"Bryan Richard S, Huang B, Liu G, et al. Impact of ivabradine on the cardiac function of chronic Heart Failure reduced ejection fraction: Meta-analysis of randomized controlled trials. Clin Cardiol. 2021;44(4):463\u201371.","journal-title":"Clin Cardiol"},{"issue":"3","key":"2042_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/00325481.2017.1259544","volume":"129","author":"R Devi","year":"2017","unstructured":"Devi R, Mali G, Chakraborty I, et al. Efficacy and safety of empagliflozin in type 2 Diabetes Mellitus: a meta-analysis of randomized controlled trials. Postgrad Med. 2017;129(3):382\u201392.","journal-title":"Postgrad Med"},{"issue":"48","key":"2042_CR12","doi-asserted-by":"publisher","first-page":"e5473","DOI":"10.1097\/MD.0000000000005473","volume":"95","author":"W Xiong","year":"2016","unstructured":"Xiong W, Xiao MY, Zhang M, et al. Efficacy and safety of canagliflozin in patients with type 2 Diabetes: a meta-analysis of randomized controlled trials. Med (Baltim). 2016;95(48):e5473.","journal-title":"Med (Baltim)"},{"key":"2042_CR13","first-page":"100725","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, et al. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"3","key":"2042_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10741-021-10083-z","volume":"27","author":"Al-abdouh Barbarawi Mahmoud","year":"2021","unstructured":"Barbarawi Mahmoud Al-abdouh, Ahmad B, Owais, et al. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2021;27(3):951\u201360.","journal-title":"Heart Fail Rev"},{"issue":"Suppl 1","key":"2042_CR15","first-page":"3","volume":"44","author":"Association American Diabetes","year":"2021","unstructured":"Association American Diabetes. Professional Practice Committee: standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):3.","journal-title":"Diabetes Care"},{"issue":"5","key":"2042_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"C Green","year":"2000","unstructured":"Green C, Patrick PCB, Bresnahan. Dennis R, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a New Health Status measure for Heart Failure. J Am Coll Cardiol. 2000;35(5):1245\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"2042_CR17","doi-asserted-by":"crossref","unstructured":"Mark S, Corbett Julian PT, Higgins, Nerys F. Woolacott. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. 2014;5(1):7.","DOI":"10.1002\/jrsm.1090"},{"issue":"1","key":"2042_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13643-017-0630-4","volume":"6","author":"B Chen","year":"2017","unstructured":"Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. 2017;6(1):243.","journal-title":"Syst Rev"},{"issue":"11","key":"2042_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","volume":"146","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Fu Z, Jones P, et al. Metabolomic profiling of the effects of Dapagliflozin in Heart Failure with reduced ejection fraction: DEFINE-HF. Circulation. 2022;146(11):808\u201318.","journal-title":"Circulation"},{"issue":"18","key":"2042_CR20","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor Sheryl L, Fengming T, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with Heart Failure with reduced ejection fraction. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"16","key":"2042_CR21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"3","key":"2042_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T, Empagliflozin, et al. Health Status, and quality of life in patients with Heart Failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation. 2022;145(3):184\u201393.","journal-title":"Circulation"},{"issue":"9","key":"2042_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","volume":"146","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for Heart Failure with preserved left ventricular ejection Fraction with and without Diabetes. Circulation. 2022;146(9):676\u201386.","journal-title":"Circulation"},{"issue":"4","key":"2042_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of patients with Heart Failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"issue":"4","key":"2042_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ejhf.2409","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Anker SD, Butler J, et al. Impact of anaemia and the effect of empagliflozin in Heart Failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022;24(4):708\u201315.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2042_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ibanez","year":"2021","unstructured":"Requena-Ibanez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9(8):578\u201389.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"2042_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized Trial of Empagliflozin in nondiabetic patients with Heart Failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2042_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","volume":"10","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10(3):184\u201397.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"2042_CR29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"7","key":"2042_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M, et al. Associations of Empagliflozin with Left ventricular volumes, Mass, and function in patients with Heart Failure and reduced ejection fraction: a Substudy of the Empire HF Randomized Clinical Trial. JAMA Cardiol. 2021;6(7):836\u201340.","journal-title":"JAMA Cardiol"},{"key":"2042_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","volume":"228","author":"J Jensen","year":"2020","unstructured":"Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with Heart Failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020;228:47\u201356.","journal-title":"Am Heart J"},{"issue":"4","key":"2042_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in Heart Failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"issue":"3","key":"2042_CR33","doi-asserted-by":"publisher","first-page":"e007767","DOI":"10.1161\/CIRCHEARTFAILURE.120.007767","volume":"14","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Birmingham MC, Butler J, et al. Novel Trial Design: CHIEF-HF. Circ Heart Fail. 2021;14(3):e007767.","journal-title":"Circ Heart Fail"},{"issue":"17","key":"2042_CR34","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin effects on Pulmonary Artery pressure in patients with Heart Failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386.","journal-title":"Circulation"},{"issue":"6","key":"2042_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of Empagliflozin on Left ventricular volumes in patients with type 2 Diabetes, or Prediabetes, and Heart Failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"2","key":"2042_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of Dapagliflozin on symptoms, function, and quality of life in patients with Heart Failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90\u20139.","journal-title":"Circulation"},{"issue":"12","key":"2042_CR37","doi-asserted-by":"publisher","first-page":"e007879","DOI":"10.1161\/CIRCHEARTFAILURE.120.007879","volume":"13","author":"SE Yeoh","year":"2020","unstructured":"Yeoh SE, Dewan P, Jhund PS, et al. Patient characteristics, clinical outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: is it ever too late to start a New Therapy? Circ Heart Fail. 2020;13(12):e007879.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"2042_CR38","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in Heart Failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"7","key":"2042_CR39","doi-asserted-by":"publisher","first-page":"e009837","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","volume":"16","author":"ME Nassif","year":"2023","unstructured":"Nassif ME, Windsor SL, Gosch K, et al. Dapagliflozin improves Heart Failure symptoms and physical limitations across the full range of Ejection Fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials. Circ Heart Fail. 2023;16(7):e009837.","journal-title":"Circ Heart Fail"},{"issue":"15","key":"2042_CR40","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/CIRCULATIONAHA.121.054669","volume":"144","author":"SD Anker","year":"2021","unstructured":"Anker SD, Ponikowski P, Wanner C, et al. Kidney function after initiation and discontinuation of Empagliflozin in patients with Heart Failure with and without type 2 Diabetes: insights from the EMPERIAL trials. Circulation. 2021;144(15):1265\u20137.","journal-title":"Circulation"},{"issue":"7","key":"2042_CR41","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ejhf.1486","volume":"21","author":"WT Abraham","year":"2019","unstructured":"Abraham WT, Ponikowski P, Brueckmann M, et al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic Heart Failure. Eur J Heart Fail. 2019;21(7):932\u201342.","journal-title":"Eur J Heart Fail"},{"key":"2042_CR42","unstructured":"ClinicalTrials.gov. DETERMINE-reduced - dapagliflozin effect on Exercise Capacity using a 6-minute walk test in patients with heart Failure With Reduced Ejection Fraction."},{"key":"2042_CR43","unstructured":"ClinicalTrials.gov. DETERMINE-preserved - dapagliflozin effect on Exercise Capacity using a 6-minute Walk Test in patients With Heart Failure With Preserved Ejection Fraction."},{"issue":"10","key":"2042_CR44","first-page":"92","volume":"34","author":"Zheng","year":"2021","unstructured":"Zheng, Huangsheng. Zhou. Bingfeng. Efficacy and prognosis of Sodium-glucose Cotransporter-2 inhibitor in treatment of Heart Failure with Lower Ejection Fraction. J Med Inform. 2021;34(10):92\u20136.","journal-title":"J Med Inform"},{"issue":"6","key":"2042_CR45","first-page":"708","volume":"14","author":"Li","year":"2022","unstructured":"Li, Huijun, Shi, Hongpo. Influence of different types of SGLT2 inhibitors on clinical prognosis in patients with Heart Failure complicated by type 2 Diabetes Mellitus. Chin J Evid Based Cardiovasc Med. 2022;14(6):708\u201310.","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"2042_CR46","unstructured":"Wu, Wenjing, Zhang. Shiyu, Liu., Cui et al. Impact of empagliflozin on peak oxygen uptake in HFmrEF patients: a randomized controlled trial. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(7):676\u2013683."},{"issue":"27","key":"2042_CR47","doi-asserted-by":"publisher","first-page":"e7201","DOI":"10.1097\/MD.0000000000007201","volume":"96","author":"J Li","year":"2017","unstructured":"Li J, Gong Y, Li C, et al. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 Diabetes Mellitus: a meta-analysis. Med (Baltim). 2017;96(27):e7201.","journal-title":"Med (Baltim)"},{"issue":"8","key":"2042_CR48","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/dom.13294","volume":"20","author":"D Li","year":"2018","unstructured":"Li D, Shi W, Wang T, et al. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 Diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(8):1972\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2042_CR49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","volume":"67","author":"M Guo","year":"2020","unstructured":"Guo M, Gu J, Teng F, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 Diabetes or obese adults: a systematic review and meta-analysis. Endocrine. 2020;67(2):294\u2013304.","journal-title":"Endocrine"},{"issue":"21","key":"2042_CR50","doi-asserted-by":"publisher","first-page":"e6944","DOI":"10.1097\/MD.0000000000006944","volume":"96","author":"Y Yang","year":"2017","unstructured":"Yang Y, Chen S, Pan H, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with Diabetes: systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2017;96(21):e6944.","journal-title":"Med (Baltim)"},{"issue":"6","key":"2042_CR51","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.13169","volume":"7","author":"J Butler","year":"2020","unstructured":"Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in Heart Failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3298\u2013309.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2042_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","volume":"21","author":"HM Salah","year":"2022","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute Heart Failure, with and without type 2 Diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):20.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2042_CR53","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.976","volume":"20","author":"E Wolsk","year":"2018","unstructured":"Wolsk E, Kaye D, Borlaug BA, et al. Resting and exercise haemodynamics in relation to six-minute walk test in patients with Heart Failure and preserved ejection fraction. Eur J Heart Fail. 2018;20(4):715\u201322.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2042_CR54","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: a thrifty substrate hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"issue":"4","key":"2042_CR55","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, Lucht CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642\u20138.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"2042_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M, et al. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by Empagliflozin. JACC Basic Transl Sci. 2019;4(5):575\u201391.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2042_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human Heart Failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase galpha oxidation. Cardiovasc Res. 2021;117(2):495\u2013507.","journal-title":"Cardiovasc Res"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02042-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:06:11Z","timestamp":1704290771000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02042-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2042"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02042-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not involve ethical approval and consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}